In pulmonary arterial hypertension, sotatercept improved primary and secondary endpoints, and thus numerous disease parameters, in a phase 3 study, in addition to standard combination therapy. The molecule targets a new mechanism of action.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- CARDIOVASC
